s6y CoLucid Pharmaceuticals, Inc. 10-Q

CoLucid Pharmaceuticals, Inc. 10-Q, filed Nov 9, 2016: IDEA: XBRL DOCUMENT

Nature of Operations - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 14, 2016
May 11, 2015
May 05, 2015
Sep. 30, 2016
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Dec. 31, 2015
Dec. 31, 2014
Basis of Presentation [Line Items]                    
Net proceeds from offering of common stock             $ 69,920 $ 49,816    
Net loss         $ (12,657) $ (8,950) (41,994) $ (27,265) $ (38,500) $ (3,000)
Accumulated deficit       $ (129,089) $ (129,089)   $ (129,089)   $ (87,095)  
Stockholders' equity, reverse stock split             one-for-40.7      
Additional shares of common stock outstanding     9,489,659              
Follow-on Public Offering [Member]                    
Basis of Presentation [Line Items]                    
Net proceeds from offering of common stock $ 69,900     $ 69,900            
Number of shares of common stock sold 3,737,500                  
Sale of stock price per share at public offering $ 20.00                  
Expenses paid by the company $ 300                  
Underwriting discounts and commissions $ 4,600                  
IPO [Member]                    
Basis of Presentation [Line Items]                    
Number of shares of common stock sold   5,500,000                
Sale of stock price per share at public offering   $ 10.00                
Net proceeds from the IPO   $ 49,800                
Expenses paid by the company   $ 1,300